Advanced glycation end-products accelerate telomere attrition and increase pro-inflammatory mediators in human WIL2-NS cells.


Journal

Mutagenesis
ISSN: 1464-3804
Titre abrégé: Mutagenesis
Pays: England
ID NLM: 8707812

Informations de publication

Date de publication:
11 07 2020
Historique:
received: 27 02 2020
accepted: 07 04 2020
pubmed: 23 4 2020
medline: 9 2 2021
entrez: 23 4 2020
Statut: ppublish

Résumé

This study investigated the effect of dietary sugars and advanced glycation end-products (AGE) on telomere dynamics in WIL2-NS cells. Dietary sugars [glucose (Glu) and fructose (Fru); 0.1 M each] were incubated with bovine serum albumin (BSA) (10 mg/ml) at 60 ± 1°C for 6 weeks to generate AGE-BSA. Liquid chromatography-mass spectrometry (LC-MS/MS) analysis showed total AGE levels as 87.74 ± 4.46 nmol/mg and 84.94 ± 4.28 nmol/mg respectively in Glu-BSA and Fru-BSA model. Cell treatment studies using WIL2-NS cells were based on either glucose, fructose (each 2.5-40 mM) or AGE-BSA (200-600 µg/ml) in a dose-dependent manner for 9 days. Telomere length (TL) was measured using qPCR. Nitric oxide (NO) production and tumour necrosis factor-α (TNF-α) levels were measured in WIL2-NS culture medium. An increasing trend for TNF-α and NO production was observed with higher concentration of glucose (R2 = 0.358; P = 0.019; R2 = 0.307; P = 0.027) and fructose (R2 = 0.669; P = 0.001; R2 = 0.339; P = 0.006). A decreasing trend for TL (R2 = 0.828; P = 0.000), and an increasing trend for NO production (R2 = 0.352; P = 0.031) were observed with increasing Glu-BSA concentrations. Fru-BSA treatment did not show significant trend on TL (R2 = 0.135; P = 0.352) with increasing concentration, however, a significant reduction was observed at 600 µg/ml (P < 0.01) when compared to BSA treatment. No trends for TNF-α levels and a decreasing trend on NO production (R2 = 0.5201; P = 0.019) was observed with increasing Fru-BSA treatment. In conclusion, this study demonstrates a potential relationship between dietary sugars, AGEs and telomere attrition. AGEs may also exert telomere shortening through the production of pro-inflammatory metabolites, which ultimately increase the risk of diabetes complications and age-related disease throughout lifespan.

Identifiants

pubmed: 32319517
pii: 5823765
doi: 10.1093/mutage/geaa012
doi:

Substances chimiques

Glycation End Products, Advanced 0
Inflammation Mediators 0
Tumor Necrosis Factor-alpha 0
advanced glycation end products-bovine serum albumin 0
Serum Albumin, Bovine 27432CM55Q
Fructose 30237-26-4
Nitric Oxide 31C4KY9ESH
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

291-297

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Permal Deo (P)

School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Health and Biomedical Innovation, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.

Varinderpal S Dhillon (VS)

School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Health and Biomedical Innovation, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.

Wai Mun Lim (WM)

School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.

Emma L Jaunay (EL)

School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Health and Biomedical Innovation, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.

Leigh Donnellan (L)

School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Health and Biomedical Innovation, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.

Brock Peake (B)

School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Health and Biomedical Innovation, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.

Caitlin McCullough (C)

School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.

Michael Fenech (M)

School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Health and Biomedical Innovation, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Genome Health Foundation, North Brighton, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH